Cantor Fitzgerald Reiterates Overweight on Celldex Therapeutics, Maintains $67 Price Target
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald has reiterated its Overweight rating on Celldex Therapeutics, maintaining a price target of $67.
September 20, 2024 | 4:13 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Cantor Fitzgerald has reiterated its Overweight rating on Celldex Therapeutics, maintaining a price target of $67, indicating confidence in the company's future performance.
The reiteration of an Overweight rating and a maintained price target of $67 by Cantor Fitzgerald suggests a positive outlook for Celldex Therapeutics. This could lead to increased investor confidence and potentially a short-term rise in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100